Sorry we’re down for maintenance

About Precision Virologics, Inc.

Precision’s technology platform provides unique opportunities to accomplish targeted genetic therapies. Our novel targeted genetic knock-in allows long term correction for gene therapy cures. Precision’s technology platform combines effective in vivo gene delivery with CRISPR/Cas9 gene editing allowing adenovirus to achieve long term correction of hemophilia and other inherited genetic disorders. Our novel vector approach allows distinct advantages compared to AAV vectors. We are presently progressing programs for hemophilia and alpha1-antitrypsin deficiency lung disease with National Institute of Health support.

Our platform vaccine approach delivers antigens directly to the key immune activating dendritic cells. This achieved optimized potency based on our unrivaled ability to target the key biologic axis orchestrating effective immunization. Vaccine candidates for Zika and Chikungunya are presently being progressed in our pipeline with National Institute of Health support.

Latest News

St. Louis-based Precision Virologics receives $500,000 investment in biologically targeted vaccines for Zika and Chikungunya
29 March, 2017
Precision Virologics enters license agreement with Washington University to develop biologically targeting vaccines for Zika and Chikungunya
21 March, 2017
Precision Virologics Awarded NIH Grant for Vaccine Program
20 March, 2019

info@precisionvx.com | 4041 Forrest Park Avenue, Saint Louis, MO 63148

Sorry we’re down for maintenance

About Precision Virologics, Inc.

Latest News

St. Louis-based Precision Virologics receives $500,000 investment in biologically targeted vaccines for Zika and Chikungunya

Precision Virologics enters license agreement with Washington University to develop biologically targeting vaccines for Zika and Chikungunya

Precision Virologics Awarded NIH Grant for Vaccine Program